犬细小病毒特异性免疫球蛋白的临床应用效果观察

doi:10.11843/j.issn.0366-6964.2021.09.032

Acta Veterinaria et Zootechnica Sinica ›› 2021, Vol. 52 ›› Issue (9): 2682-2686.doi: 10.11843/j.issn.0366-6964.2021.09.032

• RESEARCH NOTES • Previous Articles

Observation on the Clinical Application Effect of Canine Parvovirus Specific Immunoglobulin

CHEN Nianci¹, WANG Siying², CHAI Xinyan¹, ZHAO Yong¹, YANG Wanlian¹, SUN Yanzheng¹, Lü Yanli^1,2*

1. College of Veterinary Medicine, China Agricultural University, Beijing 100193, China;
2. Veterinary Teaching Hospital of China Agricultural University, Beijing 100193, China;
3. Beijing Chongyisheng Animal Hospital, Beijing 100021, China;
4. Beijing Century TAL Education Technology Co., Ltd, Beijing 100192, China

Received:2021-01-03 Online:2021-09-23 Published:2021-09-26

Abstract

Abstract: In order to explore the clinical application effect of canine parvovirus (CPV) specific immunoglobulin in the treatment of CPV disease, we collected the case records of CPV infected dogs received and treated in Animal Hospital of China Agricultural University from January 2016 to November 2019, and screened out the dogs with complete medical records and were treated with CPV monoclonal antibody or CPV specific immunoglobulin. These dogs were tracked return visit. We analyzed the total cure rate, the cure rate of each initial antibody levels and each month ages and the recovery course of those cases. The results showed that there was no significant difference between CPV specific immunoglobulin and CPV monoclonal antibody in the total cure rate and the cure rate of consistent initial antibody levels and consistent month ages (P>0.05). However, the recovery course of dogs treated with specific immunoglobulin was significantly lower than those treated with monoclonal antibody (P=0.02<0.05). The good clinical application effect of canine parvovirus specific immunoglobulin provides a new choice of drugs treating CPV disease.

Key words: canine parvovirus disease, canine parvovirus specific immunoglobulin, canine parvovirus monoclonal antibody, treatment effect

CLC Number:

S858.2925.3

CHEN Nianci, WANG Siying, CHAI Xinyan, ZHAO Yong, YANG Wanlian, SUN Yanzheng, Lü Yanli. Observation on the Clinical Application Effect of Canine Parvovirus Specific Immunoglobulin[J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(9): 2682-2686.

References 14

[1]	EUGSTER A K, NAIRN C. Diarrhea in puppies:parvovirus like particles demonstrated in their feces[J]. South West Vet, 1977, 30(1):59-60.
[2]	AGUNGPRIYONO D R, UCHIDA K, TABARU H, et al. Subacute massive necrotizing myocarditis by canine parvovirus type 2 infection with diffuse leukoencephalomalacia in a Puppy[J]. Vet Pathol, 1999, 36(1):77-80.
[3]	MEUNIER P C, COOPER B J, APPEL M J G, et al. Pathogenesis of canine parvovirus enteritis:sequential virus distribution and passive immunization studies[J]. Vet Pathol, 1985, 22(6):617-624.
[4]	FOCOSI D, ANDERSON A O, TANG J W, et al. Convalescent plasma therapy for COVID-19:state of the art[J]. Clin Microbiol Rev, 2020, 33(4):e00072-20.
[5]	周灵, 梁琳, 王宏伟, 等. 犬细小病毒免疫球蛋白对犬细小病毒中和活性的研究报告[J]. 中国兽医科学, 2016, 46(8):1009-1014.ZHOU L, LIANG L, WANG H W, et al. Report on neutralization tests of immunoglobulin against canine parvovirus[J]. Chinese Veterinary Science, 2016, 46(8):1009-1014. (in Chinese)
[6]	姜旭, 赵健, 倪婷婷, 等. 犬细小病毒免疫球蛋白的有效性评价[J]. 实验动物科学, 2020, 37(5):9-13.JIANG X, ZHAO J, NI T T, et al. Evaluation of the effectiveness of canine parvovirus immunoglobulin[J]. Laboratory Animal Science, 2020, 37(5):9-13. (in Chinese)
[7]	李六金, 屈红丽, 姜焕宏, 等. 抗犬细小病毒免疫球蛋白临床应用研究[J]. 中国兽药杂志, 2003, 37(3):46-47, 32.LI L J, QU H L, JIANG H H, et al. Application of anti-canine-parvovirus immunoglobuline in the treatmeat of CPV infection[J]. Chinese Journal of Veterinary Drug, 2003, 37(3):46-47, 32. (in Chinese)
[8]	GOODING G E, ROBINSON W F. Maternal antibody, vaccination and reproductive failure in dogs with parvovirus infection[J]. Aust Vet J, 1982, 59(6):170-174.
[9]	DECARO N, DESARIO C, ELIA G, et al. Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c[J]. New Microbiol, 2008, 31(1):125-130.
[10]	SHIMA F K, OMOBOWALE T O, ADESINA R D, et al. Molecular characterisation of canine parvoviruses from clinical samples and vaccines in Nigeria[J]. Infect Genet Evol, 2020, 85:104553.
[11]	BATTILANI M, MODUGNO F, MIRA F, et al. Molecular epidemiology of canine parvovirus type 2 in Italy from 1994 to 2017:recurrence of the CPV-2b variant[J]. BMC Vet Res, 2019, 15(1):393.
[12]	SPIBEY N, GREENWOOD N M, SUTTON D, et al. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus[J]. Vet Microbiol, 2008, 128(1-2):48-55.
[13]	SIEDEK E M, SCHMIDT H, STURE G H, et al. Vaccination with canine parvovirus type 2(CPV-2) protects against challenge with virulent CPV-2b and CPV-2c[J]. Berl Munch Tierarztl Wochenschr, 2011, 124(1-2):58-64.
[14]	DAY M J, HORZINEK M C, SCHULTZ R D. WSAVA guidelines for the vaccination of dogs and cats[J]. J Small Anim Pract, 2010, 51(6):e1-e32.

Observation on the Clinical Application Effect of Canine Parvovirus Specific Immunoglobulin

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 14

Related Articles 0

Recommended Articles

Metrics

Comments